Table 2. Association between RANBP9 expression levels and clinical parameters in colorectal cancer patients.
| Characteristic | RANBP9 expression intensity | P value* | |
|---|---|---|---|
| Low (%) | High (%) | ||
| Age, years | 0.288 | ||
| <65 | 68 (29.8) | 54 (23.7) | |
| ≥65 | 51 (22.4) | 55 (24.1) | |
| Gender | 0.572 | ||
| Male | 83 (36.4) | 72 (31.6) | |
| Female | 36 (15.8) | 37 (16.2) | |
| Tumor location | 0.014 | ||
| Right colon | 54 (23.7) | 32 (14.0) | |
| Left colon | 65 (28.5) | 77 (33.8) | |
| Differentiation | 0.236 | ||
| Well | 56 (24.6) | 60 (26.3) | |
| Poorly | 63 (27.6) | 49 (21.5) | |
| Vascular invasion | 0.057 | ||
| Present | 14 (6.1) | 5 (2.2) | |
| Absent | 105 (46.1) | 104 (45.6) | |
| Perineural invasion | 1.000 | ||
| Present | 6 (2.6) | 6 (2.6) | |
| Absent | 113 (49.6) | 103 (45.2) | |
| T stage | 0.636 | ||
| T1, 2 | 29 (12.7) | 23 (10.1) | |
| T3, 4 | 90 (39.5) | 86 (37.7) | |
| N stage | 0.349 | ||
| N0 | 64 (28.1) | 66 (28.9) | |
| N1, 2 | 55 (24.1) | 43 (18.9) | |
| TNM stages | 0.424 | ||
| I, II | 63 (27.6) | 64 (28.1) | |
| III, IV | 56 (24.6) | 45 (19.7) | |
| Serum CEA | 0.001 | ||
| Normal | 62 (27.2) | 33 (14.5) | |
| Elevated | 57 (25.0) | 76 (33.3) | |
| Post-surgical chemotherapy | 0.876 | ||
| No | 29 (12.7) | 25 (11.0) | |
| Yes | 90 (39.5) | 84 (36.8) | |
| Total | 119 (52.2) | 109 (47.8) | |
*Differences between the two groups were evaluated using χ2 test. RANBP9, RAN-binding protein 9. TNM, tumor node metastasis, CEA, carcinoembryonic antigen.